RxDoctor Payments Data

Jeffrey Friedman, MD

Internal Medicine · Newtown, CTNPI 1023048899

Payments from drug & device makers

$3,993in general payments, 2019–2025

Across 210 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$691
  • AbbVie$483
  • Exact Sciences$361
  • Boehringer Ingelheim$331
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$173
  • plus $877 from 23 others

What the payments were for

  • Food & beverage$3,993100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,993 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$175,727
Medicare patients
272
Services billed
2,725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol41$46,142
EliquisApixaban22$26,036
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$24,931
JanuviaSitagliptin Phosphate14$18,579
Breo ElliptaFluticasone/Vilanterol34$13,722
OzempicSemaglutide16$13,504
JardianceEmpagliflozin12$12,040
Rosuvastatin Calcium392$6,169
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,170
VyvanseLisdexamfetamine Dimesylate13$4,948
SynthroidLevothyroxine Sodium32$3,397
Atorvastatin Calcium263$2,896
Nebivolol Hcl36$2,726
Metoprolol Succinate126$2,698
Escitalopram Oxalate180$2,652

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$691$46,14241 claims
GSKTrelegy Ellipta, Breo Ellipta$1,078$38,65348 claims
PfizerEliquis, Paxlovid$115$27,46553 claims
Boehringer IngelheimJardiance, Stiolto Respimat$331$17,21023 claims
Novo NordiskOzempic$66$13,50416 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$35$4,94813 claims
AbbVieSynthroid$483$3,39732 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$74$2,018151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Newtown

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →